Mineralys Therapeutics Quarterly Balance Sheet
NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mineralys Therapeutics financial position
As of Jun 30, 2026, Mineralys Therapeutics reported total assets of $667.9 million, up 98.9% from a year earlier against total liabilities of $116.9 million. Shareholders' equity stood at $550.9 million, or 82.5% of assets. The company held $138.3 million in cash and equivalents against $100,000 of debt, a net cash position of $138.2 million.
The current ratio (current assets divided by current liabilities) was 34.46, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.00.
Summary generated from market data by MetaCap's automated system. Methodology
Mineralys Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 138.27M | 112.78M | 172.92M | 217.60M | 101.79M | 165.01M | 114.09M | 97.27M | 67.86M | 90.42M | 49.30M | 86.30M |
| Total Current Assets | 665.80M | 652.47M | 661.39M | 599.80M | 335.27M | 354.51M | 205.35M | 267.73M | 318.00M | 346.82M | 249.10M | 265.38M |
| Property, Plant & Equipment | 27.00K | 32.00K | 38.00K | 7.00K | 22.00K | 38.00K | 53.00K | 69.00K | 42.00K | 51.00K | 0 | — |
| Long-Term Investments | — | — | — | — | — | — | 0 | — | — | — | 2.48M | — |
| Total Assets | 667.85M | 652.86M | 661.81M | 599.95M | 335.72M | 354.94M | 205.90M | 268.25M | 318.49M | 347.25M | 251.64M | 277.56M |
| Accounts Payable | 1.07M | 1.12M | 2.02M | 1.12M | 3.16M | 373.00K | 479.00K | 3.11M | 1.71M | 4.26M | 601.00K | 5.57M |
| Total Current Liabilities | 19.32M | 14.72M | 15.11M | 23.52M | 22.17M | 13.39M | 14.65M | 31.32M | 28.40M | 19.20M | 10.48M | 13.54M |
| Long-Term Debt | 100.00K | — | — | — | — | — | — | — | — | — | — | — |
| Total Liabilities | 116.94M | 14.72M | 15.11M | 23.52M | 22.17M | 13.39M | 14.65M | 31.32M | 28.40M | 19.20M | 10.48M | 13.54M |
| Shareholders' Equity | 550.92M | 638.14M | 646.69M | 576.43M | 313.55M | 341.56M | 191.26M | 236.93M | 290.10M | 328.05M | 241.15M | 264.01M |
| Retained Earnings | -737.58M | -496.51M | -457.17M | -424.94M | -388.00M | -344.73M | -302.52M | -253.57M | -197.23M | -156.22M | -124.71M | -100.32M |
| Total Debt | 100.00K | — | — | — | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 138.17M | 112.78M | 172.92M | 217.60M | 101.79M | 165.01M | 114.09M | 97.27M | 67.86M | 90.42M | 49.30M | 86.30M |
| Shares Outstanding | 88.35M | 82.45M | 81.54M | 78.97M | 65.73M | 64.88M | 49.82M | 49.76M | 49.71M | 49.63M | 41.13M | 41.11M |
This table shows 12 quarterly periods of Mineralys Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow MLYS's reporting calendar. What is a balance sheet?